Target
c-MYC
8 abstracts
Abstract
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.Org: University Hospital Zurich, Brain Tumor Centre, University of Zurich, EORTC Headquarters, Institute of Neuropathology,
Abstract
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.Org: Department of Hematology,The First Affiliated Hospital of Chongqing Medical University, Department of Hematology and Oncology, Chongqing University Cancer Hospital, Department of Hematology Oncology, YunNan Provincial Cancer Hospital, Department of Lymphoma Medicine, Hubei Cancer Hospital, Department of Lymphoma and Hematology, Hunan Cancer Hospital,
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.Org: Boryung Corporation, Samsung Medical Center, Seoul National University Cancer Research Institute, Seoul, Republic of Korea, Seoul National University Hospital, Asan Medical Center,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Clinical characterization of MYC family proto-oncogene amplification in solid tumors from Chinese patients.Org: TangShan Central Hispital, Nanjing Simcere Medical Laboratory Science Co., Ltd., The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd,
Abstract
Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS.Org: Biolexis Therapeutics, Inc.,